

May 10<sup>th</sup>, 2021

World Journal of Clinical Oncology. Manuscript NO: 64954

**Title: Esophagogastric Junction Adenocarcinoma: Preoperative Chemoradiation or Perioperative Chemotherapy?**

Dear Editor

World Journal of Clinical Oncology

Thank you very much for revising our manuscript and for your interest in publishing this work in the World Journal of Clinical Oncology. We have responded directly to all points raised by the reviewers (our response in **bold**). Please find attached a copy of the revised manuscript with all changes highlighted. We think the peer-review process significantly improved the quality of our work and we hope it will now pass editorial scrutiny.

Sincerely,

Francisco Schlottmann MD MPH

Affiliate Professor

Department of Surgery

Hospital Aleman of Buenos Aires

Av. Pueyrredon1640, Buenos Aires, Argentina

f Schlottmann@hotmail.com

Office: 54911-4827-7000 (2808)

**Reviewer #1**

Scientific Quality: Grade C (Good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: Treatment management of Esophago-gastric Junction Adenocarcinoma is important. The sequence and choice of treatment can be confusing in some cases. In this review, the question of what should be the best treatment method is discussed in the light of the literature. It is generally well written and I think it can be useful for readers. It is an effective article to eliminate the clinical dilemma on this subject.

**Thank you very much for your comments.**

**Reviewer #2**

Scientific Quality: Grade D (Fair)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision

Specific Comments to Authors: You mentioned about the completion rate of FLOT and MAGIC regimen. Both of them were relatively lower, 50% and 37%, but you mentioned that are “acceptable”. You should discuss more about this. You described the strategy of your institution. Why do you set this strategy? Would you explain the reason along with your review?

**Thank you very much for your comments and suggestions. Regarding the completion of the MAGIC and FLOT regimens, we mentioned that “only 50% and 37% of the**

patients completed the entire perioperative FLOT or ECF treatment, respectively”, emphasizing that a low number of patients completed the treatment. This was added to the manuscript.

Our strategy and treatment selection were further explained as suggested by the reviewer.

### **Reviewer #3**

Scientific Quality: Grade C (Good)

Language Quality: Grade A (Priority publishing)

Conclusion: Minor revision

Specific Comments to Authors: This is a nicely written literature review, very pleasant to read, addressing a current hot-topic focused on the esophagogastric junction adenocarcinoma treatment. Despite it does not add further knowledge to current literature, I believe that it falls within the aims of the the "mini-review" section of the Journal. A meta-analysis of the cited studies would have probably added further appeal for readers of World Journal of Clinical Oncology and its implementation should be considered. My best regards.

**Thank you very much for all your comments. This manuscript indeed follows the “mini-review” section guidelines of the journal. We strongly agree that a meta-analysis might add more solid evidence regarding this controversial topic and we will try to work in such project in the near future.**

## Science editor

1 Scientific quality: The manuscript describes a minireviews of the esophagogastric junction adenocarcinoma. The topic is within the scope of the WJCO. (1) Classification: Grade D, Grade C and Grade C; (2) Summary of the Peer-Review Report: The authors found a nicely written literature review, very pleasant to read, addressing a current hot-topic focused on the esophagogastric junction adenocarcinoma treatment. However, the questions raised by the reviewers should be answered; and (3) Format: There are 2 tables and 1 figure. (4) References: A total of 26 references are cited, including 8 references published in the last 3 years; (5) Self-cited references: There are no self-cited references; and (6) References recommend: The authors have the right to refuse to cite improper references recommended by peer reviewer(s), especially the references published by the peer reviewer(s) themselves. If the authors found the peer reviewer(s) request the authors to cite improper references published by themselves, please send the peer reviewer's ID number to the editorialoffice@wjgnet.com. The Editorial Office will close and remove the peer reviewer from the F6Publishing system immediately.

2 Language evaluation: Classification: Grade B, Grade B and Grade A.

3 Academic norms and rules: No academic misconduct was found in the Bing search.

4 Supplementary comments: This is an invited manuscript. No financial support was obtained for the study. The topic has not previously been published in the WJCO.

5 Issues raised: (1) The "Author Contributions" section is missing. Please provide the author contributions; (2) The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to

ensure that all graphs or arrows or text portions can be reprocessed by the editor; and (3) Please obtain permission for the use of picture(s). If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights. For example, “Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc[6]”. And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable. 6 Recommendation: Conditional acceptance.

**Thank you very much for your comments.**

**The figure is indeed original and was submitted as a PowerPoint file as requested.**

**The section “Author’s contributions” was also added to the manuscript.**